SHCHealthcare · Diagnostics & ResearchSHC Stock Forecast: Sotera Health Co. Price Predictions for 2026-2027
The 10 Wall Street analysts covering Sotera Health Co. hold a median 12-month price target of $20 — +11.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 87 of 100 as at 1 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.
SHC stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Sotera Health Co. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (87): The business earns solid, repeatable profits on what it owns.
Accruals (51): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (23): Larger than most of the companies we track — more scrutinised, less often mispriced.
The rank is the raw material. Whether the rules would actually own Sotera Health Co. — and when they’d sell — is the membership.
SHC stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on SHC, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +11.2% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 24 June 2026 | Barclays | Maintains | Overweight | $18 → $19 |
| 24 June 2026 | Barclays | Maintains | Overweight | — |
| 5 June 2026 | Goldman Sachs | Initiates | Buy | — |
| 6 May 2026 | Piper Sandler | Reiterates | Overweight | — |
| 14 Apr 2026 | Barclays | Maintains | Overweight | — |
| 24 Feb 2026 | Citigroup | Maintains | Buy | — |
| 9 Jan 2026 | Piper Sandler | Upgrade | Overweight | — |
| 9 Jan 2026 | RBC Capital | Reinstates | Outperform | $24 |
| 18 Dec 2025 | William Blair | Initiates | Outperform | — |
| 13 Nov 2025 | BMO Capital | Initiates | Outperform | — |
| 5 Nov 2025 | Barclays | Maintains | Overweight | — |
| 5 Nov 2025 | JP Morgan | Maintains | Neutral | — |
| 5 Nov 2025 | Piper Sandler | Maintains | Neutral | — |
| 2 Oct 2025 | Barclays | Maintains | Overweight | — |
| 24 June 2025 | Barclays | Maintains | Overweight | — |
| 5 May 2025 | Goldman Sachs | Upgrade | Buy | — |
| 23 Apr 2025 | Piper Sandler | Maintains | Neutral | — |
| 10 Apr 2025 | Barclays | Maintains | Overweight | — |
| 28 Feb 2025 | Barclays | Maintains | Overweight | — |
| 18 Feb 2025 | Barclays | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
SHC analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Sotera Health Co. (SHC) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 44.3×
- Price / sales
- 4.4×
- Price / book
- 8.3×
- EV / EBITDA
- 12.6×
Cheaper than 18% of US stocks
Cheaper than 28% of US stocks
Cheaper than 12% of US stocks
Cheaper than 30% of US stocks
- Revenue growth (YoY)
- 10.0%
- Earnings growth (YoY)
- —
- Gross margin
- 52.5%
- Operating margin
- 31.3%
- Net margin
- 9.9%
Higher than 55% of US stocks
Higher than 67% of US stocks
Higher than 89% of US stocks
Higher than 70% of US stocks
- Return on equity
- 22.7%
- Return on assets
- 8.5%
- Dividend yield
- —
Higher than 84% of US stocks
Higher than 90% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
SHC vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SHC appears on the weeks it earns a place.
Frequently asked questions about SHC stock
What is the SHC stock price forecast for 2026-2027?
The 10 Wall Street analysts covering Sotera Health Co. have a median 12-month price target of $20, with estimates ranging from $16 to $24. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is SHC stock a buy right now?
Of the 10 analysts covering Sotera Health Co., 8 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Sotera Health Co. 87 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank SHC?
As at 1 Aug 2026, Sotera Health Co. ranks 87 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (87 of 100).
Will SHC stock go up?
No one can know that. What the data says: the median 12-month target from 10 analysts implies +11.2% from the last close, and Ticker Nerd's factor model ranks Sotera Health Co. 87 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the SHC stock forecast for 2030?
No analyst covering Sotera Health Co. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SHC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $16 to $24 over the next 12 months.
How has SHC stock performed over the past year?
Sotera Health Co. returned +61.3% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Sotera Health Co. do?
Sotera Health Company is a leading provider of mission-critical health and sterilization services. It plays a vital role in ensuring safety and compliance across medical device, pharmaceutical, food, and other industries that require stringent sterilization and laboratory testing services.
About Sotera Health Co.
Sotera Health Company is a leading provider of mission-critical health and sterilization services. It plays a vital role in ensuring safety and compliance across medical device, pharmaceutical, food, and other industries that require stringent sterilization and laboratory testing services. The company operates under three key business units: Sterigenics, Nordion, and Nelson Labs. Sterigenics provides end-to-end sterilization solutions using innovative technologies to eliminate pathogens from medical and other consumable products. Nordion is instrumental in supplying Cobalt-60 that facilitates the radiation sterilization process, essential for medical devices, pharmaceuticals, and food safety industries. Nelson Labs delivers comprehensive testing and consultancy services, supporting organizations in gaining and maintaining regulatory approvals. Sotera Health's integrated solutions are crucial for maintaining public health standards and meeting regulatory compliance, making it an indispensable entity in the global health landscape. As an established operator with a broad international presence, Sotera Health Company underscores the importance of safety and reliability in its service offerings, significantly impacting industries reliant on rigorous safety standards.
CEO Mr. Alton E. Shader · 3,000 employees · United States · https://soterahealth.com